A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In light of the recently reported neuropathologic and neurochemical abnormalities of the cholinergic pathways in autism, donepezil, a cholinesterase inhibitor, is a potentially useful agent in the treatment of cognitive and behavioral symptoms observed in this disorder. A retrospective pilot study was conducted to determine whether donepezil is effective in the treatment of children and adolescents with autism. Eight patients (mean age = 11.0 +/- 4.1 years; range 7-19 years) who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for autistic disorder were openly treated with donepezil. All patients were on concomitant psychoactive medications. Four of these patients (50%) demonstrated significant improvement as assessed by the Aberrant Behavior Checklist and the Clinical Global Impression Scale. Decreases in the Irritability and Hyperactivity subscales were observed, but no changes in the Inappropriate Speech, Lethargy, and Stereotypies subscales were noted. Limited and transient side effects were reported, with one patient experiencing gastrointestinal disturbances and another reporting mild irritability. Double-blind, placebo-controlled investigations are needed to provide further evidence of the potential benefits of donepezil to patients with autistic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropsychologic functioning in autism: Profile of a complex information processing disorder.
MINSHEW, N. J., GOLDSTEIN, G., & SIEGEL, D. J. (1997) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617797003032 · Cited by 572 · cited 1×
“Deficits in executive function, reasoning, and problem-solving abilities have been reported and are viewed as possibly contributing to the behavioral impairments in autism (Minshew et al. 1992, 1997).”
Cited by
Chauhan, A., & Chauhan, V. (2006) · Pathophysiology · doi:10.1016/j.pathophys.2006.05.007 · Cited by 656
Belmonte, M. K., Cook, E. H., Anderson, G. M., Rubenstein, J. L. R., Greenough, W. T., Beckel-Mitchener, A., Courchesne, E., Boulanger, L. M., Powell, S. B., Levitt, P. R., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001499 · Cited by 442
“Pharmacologic therapies targeting the cholinergic system may be of value; there has been one report of success using the acetylcholinesterase inhibitor donezipil to treat autistic symptoms of irritability and hyperactivity [103].”
MethodNeurochemical correlates of autistic disorder: a review of the literature
Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2005.03.003 · Cited by 318
“Hardan and Handen (2002) treated eight patients having autism with donepezil in an open trial.”
BackgroundMarotta, R., Risoleo, M. C., Messina, G., Parisi, L., Carotenuto, M., Vetri, L., & Roccella, M. (2020) · Brain Sciences · doi:10.3390/brainsci10030163 · Cited by 279
“Evidence on animal models and on men has also demonstrated that donepezil has a good safety and tolerability profile and determined an improvement in behavioral dysfunctions [99].”
BackgroundCurrent Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
Metadata
- Authors
- Hardan, A. Y., & Handen, B. L.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2002-09
- Volume
- 12
- Issue
- 3
- Pages
- 237-241
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1521522959
- Cited by
- 128
- References
- 1
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder. https://app.cochat.ai/papers/10.1089/104454602760386923
- The paper
- Hardan, A. Y., & Handen, B. L. (2002). A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/104454602760386923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.